Boston Scientific Corporation (NYSE:BSX) Given Consensus Rating of “Buy” by Analysts

Boston Scientific Corporation (NYSE:BSX) has been assigned a consensus rating of “Buy” from the twenty-five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, twenty-one have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $107.1818.

BSX has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Stifel Nicolaus lowered their target price on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Wells Fargo & Company dropped their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Finally, Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. State Street Corp increased its holdings in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Synergy Asset Management LLC increased its holdings in shares of Boston Scientific by 3,493.0% during the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after acquiring an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC raised its stake in shares of Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after acquiring an additional 14,700 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in Boston Scientific in the 3rd quarter worth approximately $26,955,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s European urology portfolio expanded with sacral neuromodulation following the Axonics deal, supporting recurring revenue growth in a defensive medtech category. Sacral neuromodulation broadening Boston Scientific’s European urology portfolio
• Positive Sentiment: Analysts continue to rate BSX as a buy: UBS and Truist trimmed price targets (UBS $120→$105; Truist $95→$92) but retained buy ratings, signaling ongoing analyst conviction even after downward target adjustments. Benzinga analyst notes
• Neutral Sentiment: Coverage pieces position Boston Scientific as a defensive healthcare hedge versus cyclically sensitive sectors, which can attract flows in volatile markets but is not an immediate catalyst. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Industry hires and competitor moves (e.g., Field Medical naming a new CEO with Medtronic experience) are notable for competitive dynamics but are not direct, immediate earnings catalysts for BSX. Field Medical appoints Mark Turco as CEO
• Negative Sentiment: Multiple law firms and plaintiff notices warn Boston Scientific investors of a securities‑class‑action covering purchases from July 23, 2025 to Feb 3, 2026, with a May 4, 2026 lead‑plaintiff deadline — this surge of legal filings/notices increases potential litigation risk and uncertainty. Rosen Law Firm investor alert
• Negative Sentiment: Specific allegations (highlighted by firms such as Levi & Korsinsky) claim executives misrepresented U.S. electrophysiology procedure volumes — if proven, these allegations could lead to meaningful financial and reputational impact. Levi & Korsinsky investor alert

Boston Scientific Stock Up 0.1%

Shares of NYSE:BSX opened at $71.29 on Friday. The firm has a 50 day simple moving average of $80.88 and a 200 day simple moving average of $92.56. Boston Scientific has a 52 week low of $67.56 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market cap of $105.78 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.